Addendum
Pembrolizumab (cervical cancer) – Addendum to Commission A22-70
Report documents
-
Addendum
Pembrolizumab (cervical cancer) – Addendum to Commission A22-70
Dossier assessment
Indication:
Adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 with a CPS ≥ 1
Result of dossier assessment:
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is a suitable therapy of physician’s choice: After addendum now: indication of major added benefit
- First-line patients for whom cisplatin or carboplatin + paclitaxel ± bevacizumab is no suitable therapy of physician’s choice: Unchanged after addendum: added benefit not proven
- Patients after first-line chemotherapy and for whom further antineoplastic therapy is an option: Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.
Project details
- Project no.
- A22-135
- Commission
- Commission awarded on 21.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed